RLMD250117C5000
- 0.05
- 0.000.00%
Relmada Therapeutics Newsroom
Relmada Therapeutics Shifts Focus After Study Discontinuation
Relmada Therapeutics Exploring Sale After Lead Program Failure
Relmada Therapeutics Announces Discontinuation of Reliance II and Relight Phase 3 Studies, Explores Strategic Alternatives
Express News | Relmada Therapeutics Inc: To Explore Strategic Alternatives
Express News | Relmada Therapeutics Inc: Will Continue to Advance Phase 1 Study of Rel-P11, an Investigational Agent for Treatment of Metabolic Disease
Express News | Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of Rel-1017
Press Release: Relmada Therapeutics to Discontinue the Reliance II and Relight Phase 3 Studies of REL-1017
Express News | Trading Halt: Halted at 7:25:00 A.m. ET - Trading Halt: Halt News Pending
Relmada Shares Continue Downward Spiral After Downgrades
Relmada Cut to Neutral by Mizuho on Phase 3 Study Failure
Mizuho Securities Downgrades Relmada Therapeutics (RLMD) to a Hold
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Relmada Therapeutics Cut to Market Perform From Outperform by Leerink Partners
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Top Midday Decliners
Relmada Therapeutics Stock Plummets Losing 80% Value - Here's Why
Nasdaq Surges 150 Points; ISM Services PMI Falls In November
Leerink Partners Downgrades Relmada Therapeutics to Market Perform From Outperform, $1 Price Target; Shares Plummet
Express News | Relmada Therapeutics Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to $0.60 From $13